Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2018-04-11 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
2017年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year ending December 31, 2017, issued by a certified public accounting firm. It contains detailed audit opinions, basis for audit opinions, key audit matters, management responsibilities, and auditor responsibilities. It includes substantive financial data such as consolidated balance sheets, income statements, and notes to the financial statements. The content is consistent with a standalone audit report rather than a full annual report or other filing types. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR).
2018-04-11 Chinese
重大资产重组之2017年度业绩承诺实现情况的说明
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the fulfillment of performance commitments related to a major asset restructuring completed in 2017. It references a special audit report on the achievement of profit targets for 2017, which is a typical disclosure related to major asset restructuring and performance guarantees. The document is relatively short (1114 characters) and primarily serves to inform shareholders and the public about the status of these commitments, referencing attached audit and verification reports. It does not contain full financial statements or comprehensive financial analysis, nor is it a full annual or interim report. It is not a proxy, voting result, or management change announcement. Therefore, this document fits best as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2018-04-11 Chinese
独立董事梁子才先生2017年度述职报告
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2017. It details the director's attendance at board and shareholder meetings, opinions on company matters, supervision of information disclosure, governance activities, and other duties performed during the year. It is a narrative report on the director's role and activities rather than a financial report, audit, or regulatory filing. It does not contain financial statements or earnings data, nor is it an announcement or proxy solicitation. This type of document fits best under Board/Management Information (MANG) as it relates to board member activities and governance roles.
2018-04-11 Chinese
独立董事李广超先生2017年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director (李广超) for the year 2017 at 成都市贝瑞和康基因技术股份有限公司. It includes attendance records at board and shareholder meetings, independent opinions on various board matters, supervision activities, and other governance-related duties. The content focuses on the director's role, governance, and oversight activities rather than financial results or audit opinions. It is not a full annual report (10-K), audit report (AR), or earnings release (ER). It is also not a brief announcement or a proxy solicitation. The document fits best under Board/Management Information (MANG) as it relates to board member activities and governance reporting by a director.
2018-04-11 Chinese
关于全资子公司医疗器械注册变更的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1047 characters) from a company about a regulatory approval related to a change in medical device registration for its wholly owned subsidiary. It details the change in product specifications and discusses the potential impact on the company. There are no financial statements, no detailed financial data, no earnings information, no management discussion, and no mention of a report being attached or published. The content is a regulatory announcement about a product registration change, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention any report release. It is not a board or management change, nor a capital or financing update. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2018-03-21 Chinese
关于对全资子公司增资事项的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of capital increase in a wholly-owned subsidiary. It details the completion of registration procedures for the capital increase and provides company registration information. The document is short (1241 characters) and focuses on a specific corporate action related to capital structure changes within subsidiaries. It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2018-03-13 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.